Other languages RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-10 EDT			5-day change	1st Jan Change
1.45 ^USD	+7.81%		+18.85%	-36.68%

04-16	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
04-15	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	04-16
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	02-23
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	02-09
RenovoRx Raises $6.1 Million From Private Placement; Shares Rise	01-29
Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee	01-02
Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer	12-21
RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform	12-13
Renovorx Appoints Michel Ducreux as Scientific Advisory Board	11-16
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16
Renovorx and Imugene Announces Researchcollaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion Platform	23-07-20
RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer	23-06-29
Top Premarket Gainers	23-06-28
RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board	23-06-20
Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial	23-06-01
RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer	23-05-25
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Renovorx, Inc. Appoints Robert J. Spiegel to Its Board of Directors	23-04-27
RenovoRx, Inc. Announces the Appointment of Leesa Gentry as Senior Vice President of Clinical Operations	23-04-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages RenovoRx, Inc.

Equities

RNXT

US75989R1077

Other languages

Filters